AUA 2022 Bladder Cancer Forum VL

The Impact of Variant Histology on the Management of Patients with Bladder Cancer - Mario Fernandez and Michael A. O’Donnell

Michael O’Donnell and Mario Fernandez join Peter Black to discuss the impact of variant histology on managing patients with bladder cancer. The conversation begins with deciding when the evidence supports preserving the bladder vs. performing a cystectomy. Then the discussion moves to other treatment options, including how the BCG shortage has led to new treatment alternatives for micropapillary b...

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...

Do We Need to Perform Radical Cystectomy for Patients Who are cT0 After Neoadjuvant Chemotherapy? - Gary Steinberg & John Taylor

The 2022 Annual Meeting of the American Urological Association (AUA) was host to The International Bladder Cancer Group (IBCG) AUA Bladder Cancer Forum which featured a case-based debate regarding the role of radical cystectomy in a patient who achieves a cT0 status after neoadjuvant chemotherapy. Drs. Gary Steinberg and John Taylor join Patrick Hensley providing highlights from their side of the...
email news signup